Ardelyx, Inc. - Common Stock (NQ:ARDX)

3.195 -0.095 (-2.89%)

Delayed Quote Updated: 10:20 AM EST, Nov 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List ↗

February 06, 2024

These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry.

Via InvestorPlace

The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 ↗

February 02, 2024

These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns

Via InvestorPlace

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

February 01, 2024

Conference call scheduled for 4:30 p.m. Eastern Time

From Ardelyx, Inc.

Via GlobeNewswire

3 Groundbreaking Biotech Stocks to Invest in Now ↗

January 29, 2024

These are several biotech companies for investors seeking unique opportunities for great returns within the industry.

Via InvestorPlace

Wedbush Maintains Outperform Rating for Ardelyx: Here's What You Need To Know ↗

January 12, 2024

Via Benzinga

Why Ardelyx Stock Is Climbing Higher ↗

January 09, 2024

Via Benzinga

What Analysts Are Saying About Ardelyx Stock ↗

January 09, 2024

Via Benzinga

What's Going On With Ardelyx Stock? ↗

January 08, 2024

Ardelyx, Inc. (NASDAQ: ARDX) shares are trading higher Monday after the company provided a strategic business update.

Via Benzinga

7 Small-Cap Stocks to Buy for Big Gains in 2024 ↗

January 29, 2024

Small-cap stocks are a great way to diversify your portfolio and set yourself up for some potentially dynamic gains.

Via InvestorPlace

3 mid-caps under $20 that Wall Street loves

January 23, 2024

MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share

Via MarketBeat

Topics Artificial Intelligence Economy

Ardelyx, Inc. Reports Employment Inducement Grants

January 12, 2024

From Ardelyx, Inc.

Via GlobeNewswire

The Latest Analyst Ratings for Ardelyx ↗

December 01, 2023

Via Benzinga

The 3 Best Under-$10 Stocks to Buy in January 2024 ↗

January 10, 2024

These are a few companies for investors looking for inexpensive options that still offer great earnings potential.

Via InvestorPlace

10 Health Care Stocks Whale Activity In Today's Session ↗

January 09, 2024

Via Benzinga

Nvidia, Boeing, Ardelyx, Crocs, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

January 08, 2024

Via Benzinga

Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities

January 08, 2024

From Ardelyx, Inc.

Via GlobeNewswire

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

January 08, 2024

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on...

Via Benzinga

Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8

January 03, 2024

Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PT

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

December 20, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study ↗

December 19, 2023

Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in

Via Benzinga

Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst ↗

December 18, 2023

Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

December 14, 2023

Via Benzinga

3 Short-Squeeze Stocks Ready for a Year-End Rally ↗

December 14, 2023

These are a few companies that have seen considerable gains this year that still have a large percentage of short interest.

Via InvestorPlace

Ardelyx, Inc. Reports Employment Inducement Grants

November 21, 2023

From Ardelyx, Inc.

Via GlobeNewswire

7 Penny Stocks You’ll Regret Not Buying Soon: November 2023 ↗

November 21, 2023

Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time.

Via InvestorPlace

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

November 21, 2023

From Ardelyx, Inc.

Via GlobeNewswire

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

November 15, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx Announces Departure of Board Member

November 13, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx to Participate at the Jefferies London Healthcare Conference

November 10, 2023

From Ardelyx, Inc.

Via GlobeNewswire

5 OTC Stocks With The Potential To Explode In 2024 ↗

November 08, 2023

Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.